摘要
Abstract
Objective:To investigate the difference of efficacy between Gemcitabine and Capecitabine in stage Ⅳ pancreatic cancer treated with FOLFIRINOX regimen.Method:68 pancreatic cancer patients with stage Ⅳ were confirmed in our hospital pathological cases,the collection time from May 2016 to May 2018,34 patients were treated with FOLFIRINOX regimen(group A),34 patients were treated with gemcitabine combined with Capecitabine therapy(group B),the clinical curative effect,prognosis and adverse reaction of two groups were compared.Result:Patients in group A of PR 68.75%, SD 25.00%, PD 6.25%,group B of PR 41.18%, SD 44.12%, PD 14.71%,the differences were statistically significant(P<0.05);the leukopenia,nausea and vomiting in group A were significantly higher than those in group B,the differences were statistically significant (P<0.05);the survival rate of 6 and 12 months of two groups had no significant difference(P>0.05);the PFS time of group A was 9 months longer than 7 months of group B (P<0.05),the OS time of group A was 10 months longer than 8 months of group B(P<0.05).Conclusion:The FOLFIRINOX regimen is superior to the Gemcitabine and Capecitabine regimen in the treatment of stage Ⅳ pancreatic cancer,but the incidence of toxic side effects is relatively high,it is a better choice for general good condition patients with stage Ⅳ pancreatic cancer.关键词
FOLFIRINOX方案/胰腺癌/吉西他滨/卡培他滨Key words
FOLFIRINOX regimen/Pancreatic cancer/Gemcitabine/Capecitabine
